Access plans increasingly part of drugmakers’ strategies, says report

While companies have increasingly included access plans in their efforts to expand access to their products in low- and middle-income countries (LMICs), there is room for improvement.

Speaking to The Hindu, James Hazel, Research Programme Manager for the 2022 Access to Medicine Index, tells journalist Jyothi Datta: “Companies must consider the depths of their plans, strength of their supply chains, and equity of their pricing strategies to reach the most vulnerable populations.”

In analysing the 2022 Index ranking, the publication also highlights one of the Key Findings of the latest Index, which is that the pipeline for R&D projects covering emerging infectious diseases (excluding COVID-19 and other coronaviral diseases) has remained mainly empty.

Read the article on The Hindu businessline website.